GlassScriptPhysician profile
Michelle Howell
NPI 1831803246
$2,571.65
in general payments reported to CMS, 2019-2025
29 companies · $2,332 in 2025
The $2,332 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $239 · 2025: $2,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $345.74 | 2025 | |
| Novo Nordisk INC | $324.12 | 2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $214.32 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.51 | 2024-2025 | Caplyta |
| Pfizer INC. | $166.21 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.03 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $140.99 | 2025 | Zoryve |
| Viatris Specialty LLC | $139.87 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $133.74 | 2024-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $103.03 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $64.59 | 2025 | Mounjaro, Kisunla |
| Lundbeck LLC | $63.58 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.58 | 2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $58.27 | 2025 | Voquezna |
| Astellas Pharma US INC | $50.02 | 2024-2025 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.20 | 2025 | |
| Amgen INC. | $39.45 | 2025 | Repatha, Evenity |
| Sumitomo Pharma America, INC. | $37.62 | 2024-2025 | Gemtesa |
| Shield Therapeutics INC | $35.77 | 2025 | |
| Esperion Therapeutics, INC. | $32.60 | 2024-2025 | Nexletol |
| Dexcom, INC. | $23.23 | 2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $22.19 | 2024 | Yupelri |
| Insulet Corporation | $21.21 | 2025 | Omnipod |
| Phadia US INC. | $20.50 | 2025 | Immunocap |
| Xeris Pharmaceuticals, INC. | $16.41 | 2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.66 | 2024 | Xifaxan |
| Glaxosmithkline, LLC. | $14.33 | 2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $14.29 | 2024 | Trintellix |
| Sanofi Pasteur INC. | $13.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.